A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

To join this study, you generally need to be an adult aged 50 or older. You must have been diagnosed with wet macular degeneration very recently, within the last three weeks, and you shouldn't have received any previous treatment for it in the eye being studied. The study is open to both men and women.

There are also some reasons why you might not be able to join. For example, if you have very high blood pressure that isn't under control, you might not be suitable. Similarly, if you've had certain eye surgeries or treatments in the past few months, like some types of laser treatment, or if you have other ongoing, active eye conditions besides your macular degeneration, you might not be able to take part.

It's important to remember that these are just some of the main points. The medical team will check all your health details carefully to make sure the study is safe and right for you.

If you decide to take part in this study, you'll have regular visits to the clinic. Over the course of the study, you'll receive either the new medicine, tiespectus, or the standard medicine, aflibercept. You won't get to choose which one you receive; it will be decided randomly, like flipping a coin. Both medicines are given as an injection into the eye, and you'll have various eye examinations and tests at each visit to check your vision and how your eye is responding.

The study involves a number of clinic visits over an extended period. The exact number and frequency of visits will be explained in detail by the study staff. You'll have thorough eye check-ups, including special scans and vision tests. There will also be general health checks to make sure you are well throughout the study. The total duration of your participation in the study, from your first visit to your final follow-up, will be clearly outlined by the study team.